NCT04366713View on ClinicalTrials.gov

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions
HER2 Amplified Breast Cancer
Interventions
DRUG

Neratinib

Administered orally once daily as a single daily dose of 240 mg

DRUG

Capecitabine

Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle

DRUG

Loperamide

Administered orally for prophylaxis for 28 days and then as needed

Trial Locations (1)

1998-018

Hospital CUF Descobertas, Lisbon

All Listed Sponsors
lead

Puma Biotechnology, Inc.

INDUSTRY

NCT04366713 - A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | Biotech Hunter | Biotech Hunter